Who
Ian Michael Estepan
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Sarepta Therapeutics.
In numbers
- Trades disclosed
- 79
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $1.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 14 Dec 2020
- Last trade
- 4 Sep 2026
- Last filed
- 8 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Sep 2026filed 8 Sep 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $551K24,799 at $22.22 | filing |
| 4 Sep 2026filed 8 Sep 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $551K24,799 at $22.22 | filing |
| 11 Mar 2026filed 13 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $19K1,097 at $17.03 | filing |
| 11 Mar 2026filed 13 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $19K1,097 at $17.03 | filing |
| 9 Mar 2026filed 11 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $18K1,036 at $16.95 | filing |
| 9 Mar 2026filed 11 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $9,882583 at $16.95 | filing |
| 9 Mar 2026filed 11 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $18K1,036 at $16.95 | filing |
| 9 Mar 2026filed 11 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $9,882583 at $16.95 | filing |
| 2 Mar 2026filed 3 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $53K3,301 at $16.20 | filing |
| 2 Mar 2026filed 3 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $14K875 at $16.20 | filing |
| 2 Mar 2026filed 3 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $53K3,301 at $16.20 | filing |
| 2 Mar 2026filed 3 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $14K875 at $16.20 | filing |
| 1 Mar 2026filed 3 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code M | —8,125 | filing |
| 1 Mar 2026filed 3 Mar 2026 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,125 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,125 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code M | —8,125 | filing |
| 26 Feb 2026filed 2 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code M | $28K2,069 at $13.71 | filing |
| 26 Feb 2026filed 2 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code M | $74K5,381 at $13.71 | filing |
| 26 Feb 2026filed 2 Mar 2026 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,069 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,069 at $0.00 | filing |
News
Contrasting Sarepta Therapeutics (NASDAQ:SRPT) & AbCellera Biologics (NASDAQ:ABCL)SRPT · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Ian Michael Estepan; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.